Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...9293949596979899100101102...123124»
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Review, Journal:  Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. (Pubmed Central) -  Dec 3, 2020   
    This trend has changed over the last 2 years with several compounds, such as lenvatinib (in first-line) and regorafenib, cabozantinib, ramucirumab and nivolumab (in second-line), showing clinical benefit...Conversely, PFS with a HR between 0.6-0.7, despite significant, was not associated with better survival, and thus these magnitudes are considered uncertain surrogates. In the current review, we discuss the reasons for positive or negative phase III trials in advanced HCC, and the strengths and limitations of clinical surrogate endpoints (PFS, TTP and objective response rate [ORR]) to predict survival.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion date, Trial primary completion date:  Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov) -  Dec 2, 2020   
    P1,  N=1000, Recruiting, 
    In the current review, we discuss the reasons for positive or negative phase III trials in advanced HCC, and the strengths and limitations of clinical surrogate endpoints (PFS, TTP and objective response rate [ORR]) to predict survival. Trial completion date: Dec 2023 --> May 2025 | Trial primary completion date: Jun 2021 --> May 2025
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment change, PD(L)-1 Biomarker:  TALENT: Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC (clinicaltrials.gov) -  Nov 27, 2020   
    P2,  N=27, Not yet recruiting, 
    Our study confirms the efficacy and safety of lenvatinib as second-line and later line treatment for patients with unresectable HCC who received sorafenib in clinical practice. N=40 --> 27
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Metastases:  Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors (clinicaltrials.gov) -  Nov 24, 2020   
    P2,  N=50, Recruiting, 
    NLR can supportively be used as a tumor marker of RR-DTC and an indicator for starting lenvatinib treatment. Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Apr 2020 --> Apr 2021
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial initiation date, PD(L)-1 Biomarker, Metastases:  Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Nov 23, 2020   
    P2,  N=76, Recruiting, 
    Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Apr 2020 --> Apr 2021 Initiation date: Oct 2020 --> Jul 2020
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal:  Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. (Pubmed Central) -  Nov 21, 2020   
    Multiple clinical trials of combination immunotherapy have been recently completed, but interpretation of the results is hampered by small samples sizes and discordant outcomes. This review summarizes recent data on emerging treatments for neuroendocrine neoplasms.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Journal, Checkpoint inhibition, MSi-H Biomarker, PD(L)-1 Biomarker, IO Biomarker:  A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer. (Pubmed Central) -  Nov 21, 2020   
    Based on substantial activity in a phase Ib/II study, the U.S. Food and Drug Administration (FDA) granted lenvatinib and pembrolizumab combination therapy accelerated approval in 2019 for the treatment of advanced endometrial cancer that is not MSI-H or dMMR and has progressed following prior therapy. Although these developments have been highly impactful, a more robust understanding of the molecular and immunologic drivers of response and resistance will be critical to optimally design next-generation studies in endometrial cancer.
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly
    [VIRTUAL] Multiple Disciplinary Team (MDT) Treatment Could Help Convert Unresectable HCC of Late Stage to Resectable () -  Nov 21, 2020 - Abstract #IHPBA2020IHPBA_790;    
    After MDT discussion, the comprehensive treatment was performed to downstage the tumor, including Lenvatinib (12mg/d), checkpoint inhibitor (Sintilimab Injection, 200mg q3w) and radiotherapy(GTV, 3.0Gyⅹ10 times) . MDT treatment could help downstage the late-stage HCC, convert unresectable HCC to resectable, as well as improve the prognosis of late-stage HCC.
  • ||||||||||  Stivarga (regorafenib) / Bayer, Nexavar (sorafenib) / Bayer, Amgen
    Clinical, Journal:  Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma. (Pubmed Central) -  Nov 19, 2020   
    Similar adverse events were experienced by patients during consecutive treatment with sorafenib and regorafenib, which was not observed during treatment with sorafenib and lenvatinib. The obtained safety profile of sorafenib provided meaningful insights for selecting sequential therapy for patients with patients with advanced HCC.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg., lenvatinib / Generic mfg.
    Journal:  Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer. (Pubmed Central) -  Nov 14, 2020   
    Lenvatinib promotes the antitumor effect of doxorubicin in ATC cell and xenograft model. The lenvatinib/doxorubicin combination may be a potential candidate therapeutic approach for anaplastic thyroid cancer.